Review Article
Oral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis: Tofacitinib
Table 2
Change in HAQ-DI score at month 3 (from baseline).
| Study | Total () | Tofacitinib 5 mg bd | Tofacitinib 10 mg bd | Placebo | Adalimumab 40 mg every 2 weeks |
| Burmester et al. [15] | 399 | −0.43 | −0.46 | −0.18 | — | Fleischmann et al. [16] | 611 | −0.50** | −0.57** | −0.19 | — | Kremer et al. [17]
| 792 | −0.46 | −0.56 | −0.21 | — | van der Heijde et al. [18] | 797 | −0.40# | −0.54 | −0.15 | — | van Vollenhoven et al. [19] | 717 | −0.55** | −0.61** | −0.24 | −0.49** | Fleischmann et al. [20] | 384 | −0.51* | −0.66 | −0.25 | — | Kremer et al. [21]
| 507 | −0.49** | −0.39* | −0.16 | — | Tanaka et al. [22] | 140
| −0.49** | −0.57** | −0.05 | — |
|
|
Significant ; **significant ; significant ; #significance not declared.
|